Preclinical and dose-ranging assessment of hESC-derived dopaminergic progenitors for a clinical trial on Parkinson's disease
Cell Stem Cell · 2024-01 · 31 (1) · 25-38.e8
DOI: 10.1016/j.stem.2023.11.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Stem Cell, 2024-01. Verfasst von Sanghyun Park und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea. Hauptthemen laut MEDLINE: Parkinson Disease, Human Embryonic Stem Cells. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Human embryonic stem cell (hESC)-derived midbrain dopaminergic (mDA) cell transplantation is a promising therapeutic strategy for Parkinson's disease (PD). Here, we present the derivation of high-purity mDA progenitors from clinical-grade hESCs on a large scale under rigorous good manufacturing practice (GMP) conditions. We also assessed the toxicity, biodistribution, and tumorigenicity of these cells in immunodeficient rats in good laboratory practice (GLP)-compliant facilities. Various doses of mDA progenitors were transplanted into hemi-parkinsonian rats, and a significant dose-dependent behavioral improvement was observed with a minimal effective dose range of 5,000-10,000 mDA progenitor cells. These results provided insights into determining a low cell dosage (3.15 million cells) for human clinical trials. Based on these results, approval for a phase 1/2a clinical trial for PD cell therapy was obtained from the Ministry of Food and Drug Safety in Korea, and a clinical trial for treating patients with PD has commenced.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
- S. Biomedics Co., Ltd., Seoul 04797, Republic of Korea.
- Department of Physiology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea; S. Biomedics Co., Ltd., Seoul 04797, Republic of Korea.
- Department of Physiology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea; Brain Korea, 21 PLUS Program for Medical Science, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
- Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seongnam 13620, Gyeonggi-do, Republic of Korea.
- Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Republic of Korea; Department of Pediatrics, Korea University College of Medicine, Guro Hospital, Seoul 08308, Repu…
Zitieren
APA
Park, S., Park, C. W., Eom, J. H., Jo, M. Y., Hur, H. J., Choi, S. K., Lee, J. S., Nam, S. T., Jo, K. S., Oh, Y. W., Lee, J., Kim, S., Kim, D. H., Park, C. Y., Kim, S. J., Lee, H. Y., Cho, M. S., Kim, D. S., & Kim, D. W. (2024). Preclinical and dose-ranging assessment of hESC-derived dopaminergic progenitors for a clinical trial on Parkinson's disease. Cell Stem Cell, 31(1), 25-38.e8. https://doi.org/10.1016/j.stem.2023.11.009
Vancouver
Park S, Park CW, Eom JH, Jo MY, Hur HJ, Choi SK, et al. Preclinical and dose-ranging assessment of hESC-derived dopaminergic progenitors for a clinical trial on Parkinson's disease. Cell Stem Cell. 2024;31(1):25-38.e8. doi:10.1016/j.stem.2023.11.009
BibTeX
@article{Park2024,
author = {Park, Sanghyun and Park, Chan Wook and Eom, Jang Hyeon and Jo, Mi-Young and Hur, Hye-Jin and Choi, Sung Kyoung and Lee, Jae Souk and Nam, Seung Taek and Jo, Ki-Sang and Oh, Young Woo and Lee, Jungil and Kim, Sieun and Kim, Do-Hun and Park, Chul-Yong and Kim, Su Jin and Lee, Ho-Young and Cho, Myung Soo and Kim, Dae-Sung and Kim, Dong-Wook},
title = {Preclinical and dose-ranging assessment of hESC-derived dopaminergic progenitors for a clinical trial on Parkinson's disease},
journal = {Cell Stem Cell},
year = {2024},
volume = {31},
number = {1},
pages = {25--38.e8},
doi = {10.1016/j.stem.2023.11.009}
}
EUVIMED